One-time base editing for sickle cell disease met its goal of a year free of severe crises, Beam says
Beam says its one-time treatment using base editing for sickle cell disease met its pivotal goal of a year free of severe crises; an FDA filing may follow.
Beam Therapeutics said on November 10, 2026, that its one-time sickle cell treatment risto-cel met its pivotal trial's main goal: freedom from severe pain crises for at least 12 straight months. Risto-cel uses base editing for sickle cell disease, and the Cambridge, Massachusetts company plans to ask the FDA for approval as early as the end of 2026.
Key points
- Beam Therapeutics says the BEACON Phase 1/2 trial of risto-cel met its primary efficacy endpoint: freedom from severe vaso-occlusive crises for at least 12 consecutive months, based on independently adjudicated results.
- The company says the trial also met all primary safety endpoints at a prespecified interim analysis, and all secondary endpoints, including a year free of hospital admission for severe crises.
- As of the October 20, 2026 data cutoff, 39 adults and 10 adolescents had been treated, and 31 patients had completed the follow-up needed for the main endpoint, according to Beam.
- Beam expects to file a Biologics License Application with the FDA as early as year-end 2026, which it says could be the first such application for a base-editing therapy.
- Results from an earlier data cutoff will be presented orally at the 68th American Society of Hematology Annual Meeting in New Orleans, December 12–15, 2026, with detailed pivotal results planned for a medical meeting in 2027.
Why does a year without severe pain crises matter in sickle cell disease?
Because severe vaso-occlusive crises are what put people with sickle cell disease in hospital, again and again. In a study of 20,909 U.S. patients in Medicaid claims from 2009 to 2013, 30.86% of adults and 21.87% of children had a crisis that needed an inpatient stay within their first year of follow-up, and adults averaged 142.20 crises per 100 person-years (Shah et al., Journal of Health Economics and Outcomes Research, 2019).
The crises happen when sickle-shaped red blood cells block blood vessels, causing severe pain. Sickle cell disease affects about 100,000 people in the U.S., according to the FDA, and Beam's release puts the global number at about eight million.
How does risto-cel work?
Risto-cel takes a patient's own blood stem cells, edits them, and returns them in a stem cell transplant. Beam says the edit targets the promoter regions of the HBG1/2 genes so that the repressor BCL11A can no longer bind there, which is meant to raise production of fetal hemoglobin, a form of hemoglobin that does not sickle.
Base editing changes a single DNA letter without cutting both strands of the DNA, the company says. The approach is designed to mimic people who naturally keep making fetal hemoglobin into adulthood. Treatment involves collecting stem cells after plerixafor mobilization and busulfan conditioning before the edited cells are transplanted back; Beam says the trial's safety findings were consistent with the known effects of those steps and of sickle cell disease itself.
The achievement of our primary efficacy endpoint, supported by the broader clinical safety and efficacy profile observed in the BEACON trial, reinforces our confidence in risto-cel. With these results in hand, we are focused on submitting our planned BLA as early as year-end, which has the potential to be the first BLA for a base editing therapy.
— John Evans, Chief Executive Officer, Beam Therapeutics
What does this mean for base editing for sickle cell disease?
Our analysis: these are the results Beam has said it will take to the FDA, so the next milestone is the filing itself, which the company expects as early as the end of 2026. The FDA approved the first two cell-based gene therapies for sickle cell disease, Casgevy and Lyfgenia, for patients 12 and older on December 8, 2023 (FDA). Beam says its filing for risto-cel could be the first Biologics License Application for any base-editing therapy, and BEACON treated both adults and adolescents. Clinicians and patients will see more of the data at ASH in December, and the full pivotal results in 2027.
One-time cell therapies are reaching long follow-up in other diseases too: half of myeloma patients given one CAR-T infusion after an early relapse were progression-free five years on, and the suppliers behind cell engineering are consolidating, as in MaxCyte's $151.8M Akron Bio deal.
Frequently asked questions
What is risto-cel?
Risto-cel, short for ristoglogene autogetemcel and formerly called BEAM-101, is Beam Therapeutics' investigational one-time cell therapy for sickle cell disease, made from a patient's own base-edited blood stem cells.
When will Beam submit risto-cel to the FDA?
Beam says it expects to submit a Biologics License Application for risto-cel as early as the end of 2026.
Who was treated in the BEACON trial?
According to Beam, 39 adults and 10 adolescents with sickle cell disease and severe vaso-occlusive crises had been treated by the October 20, 2026 data cutoff.
Where will more BEACON data be presented?
Beam will give an oral presentation of earlier-cutoff BEACON results at the 68th ASH Annual Meeting in New Orleans, December 12–15, 2026, and plans to present detailed pivotal results at a medical meeting in 2027.
What is Beam Therapeutics' stock ticker?
Beam Therapeutics trades on the Nasdaq under the symbol BEAM.
Sources
- Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease: press release from Beam Therapeutics via GlobeNewswire, 10 November 2026.
- Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study: Shah N. et al., Journal of Health Economics and Outcomes Research, 2019.
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease: U.S. Food and Drug Administration announcement, 8 December 2023.
- Beam Therapeutics: the company's website.